Immune Therapeutics, Inc. (OTCQB: IMUN) is positioned as a
specialty pharmaceutical company focused on manufacturing, marketing and
distributing novel patented therapies to fight chronic, life-threatening
diseases. The company achieves this by way of the activation and modulation of
the body’s immune system. Immune Therapeutics’ technology platform is built on
two different immunotherapies, Low Dose Naltrexone (LDN) and
Methionine-Enkephalin (MENK). These therapies have required decades to develop
thanks to work at institutions like the Pennsylvania State University Medical
School at Hershey, the State University of New York, the University of Chicago,
and the Multiple Sclerosis Center at UCSF. Spearheading efforts at these
institutions were Dr. Nicholas Plotnikoff, Dr. Jaquelyn McCandless, Dr. Jill
Smith, Dr. Ronald Herberman, Dr. Bernard Bihari, Ian S. Zagon, and Patricia
McLaughlin.
Over the previous two years, IMUN has funneled its resources
toward acquiring regulatory approval in emerging and developing nations for
LDN, marketed under the brand name Lodonal™. Lodonal™ is considered a highly
innovative immunotherapy for the treatment of HIV/AIDS, opportunistic
infections, cancer and autoimmune diseases. The company’s proprietary Opiate
and T Cell Receptor technology leverages the body’s immune system for
identifying and killing diseased cells.
It has become widely known that African countries endure the
greatest disease burden on the planet, with HIV/AIDS, TB and malaria being the
highest threats. In addition to the burden developing nations are now
experiencing, there is the additional burden of a rise in non-communicable
diseases, including cancer, diabetes and inflammatory disease. Despite drugs
being readily available in developing nations, the drugs are often too
expensive and difficult to administer and cause significant side effects.
LDN is viewed as a solution to these problems. Existing
treatments for cancer, HIV/AIDS, and autoimmune disease suppress the body’s
immune system, while Lodonal (LDN) is an immune modulator used to rebalance or
stimulate the immune system. The result is an improved quality of life for
those who are inflicted with these diseases. The biggest treatment hurdle in
developing nations is an inability to administer chemotherapy to people whose
immune systems have been compromised. IMUN’s platform offsets this challenge by
delivering affordable medications that are easy to administer.
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment